Ichnos Sciences Inc., a US-based clinical-stage global biotechnology company developing innovative multi-specific antibodies for oncology, announced on Monday that it has chosen ISB 2001, its first TREAT1 trispecific antibody, which engages BCMA x CD38 x CD3, as its next candidate to transfer into clinical development.
The firm has commenced IND-enabling studies for relapsed/refractory multiple myeloma and intends to advance ISB 2001 to a first-in-human study once approval from the health authorities is received in 2023.
The product is the first T cell-engaging antibody that is aimed at BCMA and CD38 on multiple myeloma cells. It is a trispecific antibody based on BEAT 2.0 technology.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886